$19.55
+0.05 (+0.26%)
Open$19.09
Previous Close$19.50
Day High$19.71
Day Low$18.81
52W High$29.16
52W Low$14.72
Volume—
Avg Volume154.3K
Market Cap1.04B
P/E Ratio—
EPS$-1.26
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 6.83M | 9.1K | 117.17M |
| Net Income | -67,025,347 | -50,362 | -10,038,830 |
| Profit Margin | -980.9% | -582.6% | -8.6% |
| EBITDA | -76,155,241 | -48,936 | -16,056,956 |
| Free Cash Flow | — | — | -11,744,338 |
| Rev Growth | +147.5% | +60.5% | +1.7% |
| Debt/Equity | — | 0.51 | 0.08 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |